ArticleClinical case reports2022

Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series.

Xenofon Baraliakos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.